Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Jul 5:16:941810.
doi: 10.3389/fnins.2022.941810. eCollection 2022.

Editorial: Disruption of the Microbiota-Gut-Brain Axis in Functional Dyspepsia and Gastroparesis: Mechanisms and Clinical Implications

Lucas Wauters  1 , Hui Li  2 , Nicholas J Talley  3   4
Affiliations
Editorial

Editorial: Disruption of the Microbiota-Gut-Brain Axis in Functional Dyspepsia and Gastroparesis: Mechanisms and Clinical Implications

Lucas Wauters et al. Front Neurosci. .
No abstract available

Keywords: disorders of gut-brain interaction (DGBI); functional dyspepsia (FD); functional gastrointestinal disorders (FGID); gastrointestinal (GI); microbiota-gut-brain axis (MGBA); small bowel bacterial overgrowth (SIBO).

PubMed Disclaimer

Conflict of interest statement

NT reports, personal fees from, Allakos (gastric eosinophilic disease) (2021), Bayer [IBS] (2020), Planet Innovation (Gas capsule IBS) (2020), Takeda, Japan (gastroparesis) (2019), Viscera Labs, (USA 2021) (IBS-diarrhoea), Dr Falk Pharma (2020) (EoE), Glutagen (2020) (Celiac disease), IsoThrive (2021) (oesophageal microbiome), BluMaiden (2021), Rose Pharma (2021), Intrinsic Medicine (2021), Comvita Mānuka Honey (2021), Reckitt (2022) outside the submitted work. NT has a patent Nepean Dyspepsia Index (NDI) 1998, Biomarkers of IBS licensed, a patent Licensing Questionnaires Talley Bowel Disease Questionnaire licensed to Mayo/Talley, a patent Nestec European Patent licensed, and a patent Singapore Provisional Patent “Microbiota Modulation Of BDNF Tissue Repair Pathway” issued, “Diagnostic marker for functional gastrointestinal disorders” AustraWautersan Provisional Patent Application 2021901692. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Reviews and research focusing on the disruption of the microbiota-gut-brain axis in functional dyspepsia and gastroparesis. This figure was created with elements from Smartservier.
See this image and copyright information in PMC

Comment on

  • The Editorial on the Research Topic Disruption of the Microbiota-Gut-Brain Axis in Functional Dyspepsia and Gastroparesis: Mechanisms and Clinical Implications

References

    1. Brown G., Hoedt E. C., Keely S., Shah A., Walker M. M., Holtmann G., et al. (2022). Role of the duodenal microbiota in functional dyspepsia. Neurogastroenterol. Motil. e14372. 10.1111/nmo.14372 - DOI - PMC - PubMed
    1. Cirillo C., Bessissow T., Desmet A.-S., Vanheel H., Tack J., Berghe P. V. (2015). Evidence for neuronal structural changes in submucous ganglia of patients with functional dyspepsia. Am. J. Gastroenterol. 110, 1205–15. 10.1038/ajg.2015.158 - DOI - PubMed
    1. Drossman D. A., Hasler W. L., Rome G. I. (2016). Functional disorders: disorders of gut-brain interaction. Gastroenterology 150, 1257–1261. 10.1053/j.gastro.2016.03.035 - DOI - PubMed
    1. Gurusamy S. R., Shah A., Talley N. J., Koloski N., Jones M. P., Walker M. M., et al. (2021). Small intestinal bacterial overgrowth in functional dyspepsia: a systematic review and meta-analysis. Am. J. Gastroenterol. 116, 935–942. 10.14309/ajg.0000000000001197 - DOI - PubMed
    1. Moshiree B., Potter M., Talley N. J. (2019). Epidemiology and pathophysiology of gastroparesis. Gastrointest. Endosc. Clin. N. Am. 29, 1–14. 10.1016/j.giec.2018.08.010 - DOI - PubMed

Publication types

LinkOut - more resources